27339305|t|A peptide from human β thymosin as a platform for the development of new anti-biofilm agents for Staphylococcus spp. and Pseudomonas aeruginosa
27339305|a|Conventional antibiotics might fail in the treatment of biofilm -associated infections causing infection recurrence and chronicity. The search for antimicrobial peptides has been performed with the aim to discover novel anti-infective agents active on pathogens in both planktonic and biofilm associated forms. The fragment 9-19 of human thymosin β4 was studied through 1 μs MD simulation. Two main conformations of the peptide were detected, both constituted by a central hydrophobic core and by the presence of peripheral charged residues suggesting a possible mechanism of interaction with two models of biological membranes, related to eukaryotic or bacterial membrane respectively. In addition, the peptide was chemically synthesized and its antimicrobial activity was tested in vitro against planktonic and biofilm form of a group of reference strains of Staphylococcus spp. and one P. aeruginosa strain. The human thymosin β4 fragment EIEKFDKSKLK showed antibacterial activity against staphylococcal strains and Pseudomonas aeruginosa ATCC 15442 at concentrations from 12.5 to 6.2 mg/ml and inhibited biofilm formation at sub-inhibitory concentrations (3.1-0.75 mg/ml). The activity of the fragment in inhibiting biofilm formation, could be due to the conformations highlighted by the MD simulations, suggesting its interaction with the bacterial membrane. Human thymosin β4 fragment can be considered a promising lead compound to develop novel synthetic or recombinant derivatives with improved pharmaceutical potential.
27339305	2	9	peptide	T116	C0030956
27339305	15	31	human β thymosin	T116	C1999611
27339305	73	85	anti-biofilm	T024	C3548526
27339305	73	92	anti-biofilm agents	T121	C1254351
27339305	97	116	Staphylococcus spp.	T007	C4275190
27339305	121	143	Pseudomonas aeruginosa	T007	C0033809
27339305	157	168	antibiotics	T195	C0003232
27339305	200	207	biofilm	T007	C0081786
27339305	220	230	infections	T046	C3714514
27339305	239	248	infection	T046	C3714514
27339305	249	259	recurrence	T046	C2825055
27339305	264	274	chronicity	T079	C0547045
27339305	291	313	antimicrobial peptides	T116,T121	C4084937
27339305	349	357	discover	T052	C1880355
27339305	364	385	anti-infective agents	T121	C0003204
27339305	386	392	active	T169	C0205177
27339305	396	405	pathogens	T001	C0450254
27339305	414	424	planktonic	T007,T204	C0032071
27339305	429	436	biofilm	T007	C0081786
27339305	459	467	fragment	T116,T130	C1335533
27339305	476	493	human thymosin β4	T116	C1999611
27339305	498	505	studied	T062	C2603343
27339305	519	532	MD simulation	T066	C2717775
27339305	543	571	conformations of the peptide	T082	C1518960
27339305	609	633	central hydrophobic core	T082	C0205099
27339305	657	667	peripheral	T082	C0205100
27339305	676	684	residues	T077	C1709915
27339305	720	731	interaction	T169	C1704675
27339305	741	747	models	T170	C3161035
27339305	751	771	biological membranes	T026	C0682529
27339305	784	794	eukaryotic	T204	C0684063
27339305	798	816	bacterial membrane	T026	C0682529
27339305	848	855	peptide	T116	C0030956
27339305	891	913	antimicrobial activity	T034	C1271650
27339305	925	933	in vitro	T062	C0681828
27339305	942	952	planktonic	T007,T204	C0032071
27339305	957	964	biofilm	T007	C0081786
27339305	975	980	group	T078	C0441833
27339305	994	1001	strains	T001	C1518614
27339305	1005	1024	Staphylococcus spp.	T007	C4275190
27339305	1033	1046	P. aeruginosa	T007	C0033809
27339305	1047	1053	strain	T001	C1518614
27339305	1059	1076	human thymosin β4	T116	C1999611
27339305	1077	1085	fragment	T116,T130	C1335533
27339305	1086	1097	EIEKFDKSKLK	T087	C0002518
27339305	1105	1127	antibacterial activity	T044	C1149575
27339305	1136	1150	staphylococcal	T007	C0038170
27339305	1151	1158	strains	T001	C1518614
27339305	1163	1185	Pseudomonas aeruginosa	T007	C0033809
27339305	1200	1214	concentrations	T081	C0560150
27339305	1252	1269	biofilm formation	T043	C1325881
27339305	1273	1302	sub-inhibitory concentrations	T081	C0600495
27339305	1325	1333	activity	T052	C0441655
27339305	1341	1349	fragment	T116,T130	C1335533
27339305	1364	1381	biofilm formation	T043	C1325881
27339305	1403	1416	conformations	T082	C1518960
27339305	1436	1450	MD simulations	T066	C2717775
27339305	1467	1478	interaction	T169	C1704675
27339305	1488	1506	bacterial membrane	T026	C0682529
27339305	1508	1525	Human thymosin β4	T116	C1999611
27339305	1526	1534	fragment	T116,T130	C1335533
27339305	1565	1578	lead compound	T121	C1254351
27339305	1609	1632	recombinant derivatives	T116	C0034861
27339305	1647	1661	pharmaceutical	T091	C0008003